

SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure 1. Changes in Mean Transvalvular Gradient Over Time.

A. Changes in the mean transvalvular gradient post-TAVR in the entire study population.

B. Changes in mean transvalvular gradient post-TAVR, according to the presence of anticoagulation therapy at hospital discharge.

Supplemental Figure 2. Incidence of Valve Hemodynamic Deterioration, According to Anticoagulation Therapy.

Supplemental Figure 3. Individual Changes in Transvalvular Gradients Over Time Among 19 Patients with Valve Hemodynamic Deterioration at 1-Year Follow-Up.

Supplemental Figure 4. Kaplan-Meier Survival Curves Following TAVR, According to Valve Hemodynamic Deterioration.

A. Global death.

B. Cardiovascular death.

C. Stroke.

SUPPLEMENTAL TABLES

Supplemental Table 1. Variables included in the propensity analysis.

<i>Variables</i>	OR (95% CI)	P value
Age	1.03 (1.01-1.04)	<0.001
Previous coronary artery disease	0.68 (0.56-0.82)	<0.001
COPD	1.11 (0.90-1.36)	0.346
Mean gradient (baseline)	0.98 (0.97-0.99)	<0.001
LVEF (baseline)	0.85 (0.69-1.05)	0.133
Prosthesis size	1.09 (0.86-1.37)	0.477
Approach	0.63 (0.49-0.81)	<0.001
Valve type	1.07 (0.87-1.32)	0.490

Supplemental Table 2. Baseline and Procedural Characteristics of the Study Population, According to Anticoagulation/DAPT Therapy at Hospital Discharge

	Anticoagulation/DAPT Therapy		
	DAPT n=1326	Anticoagulation n=707	P value
Age (years)	80.9±7.2	81.7±6.4	0.018
Male sex	600 (45.5)	333 (47.5)	0.399
Body mass index (kg/m ²)	27.3±5.1	27.1±5.2	0.494
Diabetes mellitus	404 (31.4)	205 (29.9)	0.539
Coronary artery disease	723 (55.0)	323 (46.0)	<0.001
COPD	347 (26.4)	206 (29.4)	0.143
Atrial Fibrillation	131(10)	573 (80.9)	<0.001
CKD (eGFR <60 ml/min)	887 (66.9)	496 (70.2)	0.135
STS	7.1±6.1	7.9±5.9	0.037
Baseline echocardiogram			
LVEF≥50%	958 (72.3)	483 (68.3)	0.065
Mean gradient (mm Hg)	48.7±16.1	45.2±15.1	<0.001
Aortic regurgitation			
None/Trace	799 (65.2)	406 (63.1)	
Mild	326 (26.6)	188 (29.2)	
Moderate	78 (6.4)	41 (6.4)	0.562
Severe	22 (1.8)	8 (1.2)	
Procedural			
Approach			
Transfemoral	1160 (87.5)	513 (77.9)	
Transapical/transaortic	166 (12.5)	146 (22.2)	<0.001
Prosthesis type			
Balloon expandable	526 (39.7)	346 (48.9)	
Cribier Edwards	37 (2.8)	22 (3.1)	
Sapien	179 (13.5)	129 (18.3)	
Sapien XT	252 (19.0)	176 (24.9)	
Sapien 3	58 (4.3)	19 (2.7)	
Self-expandable	800 (60.4)	361 (51.1)	
Corevalve	672 (50.7)	291(41.2)	<0.001*
Evolut R	65 (4.9)	40 (5.7)	
Portico	11 (0.8)	3 (0.4)	
DirectFlow	40 (3.0)	14 (1.9)	
Lotus	11 (0.8)	11 (1.6)	
Other	1 (0.1)	2 (0.3)	
Valve size			
≤23 mm	330 (24.9)	201 (28.4)	
>23 mm	996 (75.1)	506 (71.6)	0.089
Discharge echocardiogram			

LVEF \geq 50%	1032 (77.8)	524 (74.1)	0.062
Mean gradient (mm Hg)	9.7 \pm 4.5	9.4 \pm 4.5	0.084
Aortic regurgitation			
None/Trace	1053 (80.1)	565 (81.2)	
Mild	240 (18.3)	117 (16.8)	0.487
Moderate	22 (1.7)	13 (1.9)	
Severe	0	1 (0.1)	
Discharge medication			
Aspirin	1326 (100)	391 (56.0)	<0.001
Clopidogrel	1326 (100)	226 (32.4)	<0.001
VHD	45 (3.4)	4 (0.6)	<0.001

CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; LVEF: Left Ventricular Ejection Fraction. VHD: Valve Hemodynamic Deterioration
*vs. Balloon expandable